SALT LAKE CITY, Feb. 22, 2007 (PRIME NEWSWIRE) -- LipidViro Tech, Inc. (OTCBB:LPVT), a development-stage medical device company, announced the formation of a six-member scientific advisory panel made up of leading academicians and clinicians in neurology, radiology, microbiology and other related fields, to advise the Company on, and assist with, research and commercial development of its proprietary d-OSAB multiple-therapeutic platform.
The Company has targeted ischemic brain stroke and chronic heart failure as its two initial clinical indications. LipidViro is scheduling a 100-patient phase IIa study utilizing d-OSAB for treating patients who have suffered an ischemic brain stroke.
LipidViro d-OSAB is designed to generate multiple therapeutics from a single platform allowing the Company to leverage one-time design costs across multiple products thereby shortening subsequent product development cycles. d-OSAB technology and intellectual property were developed, and are exclusively owned, by LipidViro.
Co-Founder and Head of Research, J. Salvatore Latino said, "We are honored to have a team of such accomplished and successful professionals who will be sharing their expertise and contributing support to our business plans. Their guidance will also help us evaluate opportunities for future product development, commercialization, licensing, and distribution."
LipidViro Tech Panel of Scientific Advisors comprises:
Jacqueline Bello, M.D., Professor of Clinical Radiology at Albert Einstein College of Medicine, Bronx, NY; and Director of Neuroradiology at Montefiore Medical Center, Bronx, NY.
Myron Ginsberg, M.D., holder of the Peritz Scheinberg Endowed Chair in Neurology at the University of Miami School of Medicine.
Byron Murray, Ph.D., Professor in the Department of Microbiology and Molecular Biology at Brigham Young University.
Marilyn Rymer, M.D., Professor of Medicine at Saint Luke's Hospital, Kansas City, MO, Medical Director of the Hospital's Stroke program and the Medical Director of the Mid-America Brain and Stroke Institute. Dr. Rymer holds the Edward T. Matheny Jr. Missouri Endowed Chair in Neuroscience and is the National Chair of several stroke-related initiatives. Dr. Rymer co-founded the Center for Clinical Neurologic Studies, L.C., in Kansas City, MO., and is also on the steering committee for the National Stroke Association Stroke Center Network.
Tonmoy Sharma, MSc, MRCPsych, Ph.D., is the founder of, and chief scientific consultant to, The Cognition Group, which is involved in assessing computerized methods of cognition and training of investigators on clinical rating scales in Central Nervous System worldwide.
David S. Ucker, Ph.D., Professor in the Department of Microbiology and Immunology at the University of Illinois, Chicago, and an associate member of the Division of Immunology at the Medical Biology Institute in La Jolla, CA. He is a member and chair of the National Institutes of Health and associate editor of the Journal of Immunology.
About LipidViro Tech, Inc.
LipidViro Tech, Inc. is an early-stage biotechnology company engaged in research and commercial development of d-OSAB, a multi-therapeutic device-based platform. The Company's first commercial therapeutics target Ischemic Brain Stroke and Chronic Heart Failure, two diseases with few viable treatment options and markets exceeding $20 billion annually.
During 2007, LipidViro is scheduled to commence a 100-patient Phase IIa study treating patients who have suffered an ischemic brain stroke. d-OSAB targets the untreated stroke population estimated to exceed 94% of individuals afflicted with ischemic stroke.
Stroke is the second leading cause of death worldwide, responsible for 4.4 million deaths each year. Annually, stroke strikes more than 1.7 million people in the U.S. and EU. Seven percent of ischemic stroke patients die within 30 days, 25% die within one year. More than 50% of surviving patients have permanent disabilities that require nursing home or other long-term care. The single approved therapeutic for ischemic brain stroke patients is Tissue Plasminogen Activator (tPA). Patients are only eligible for tPA during a three-hour window from time of stroke; tPA use after three hours causes bleeding in the brain which may prove fatal. Consequently, approximately 6% of U.S. stroke patients and less than 1% of EU stroke patients utilize tPA.